profit from every $100 of sales.
$0$100
Pulse Biosciences
$50.44-3.46% today
+256.7% in 1 year
1-year low $12.661-year high $58.17
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
It holds more cash than debt.
No debt5 years
Money in, money out
What Pulse Biosciences sold, what it kept, and what it did with the cash.
Sales went from $700,000 in 2022 to $350,000 in 2025, with -$72.8 million of profit last year.
SalesProfit
Pulse Biosciences vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Pulse Biosciences | No profit yet | ||
 Intuitive Surgical | 53.8× · Expensive | ||
 EssilorLuxottica Société anonyme | 36.1× · Expensive | ||
 Becton, Dickinson and | 35.4× · Expensive | ||
 Medline | 44.8× · Expensive |
AI analysis
An AI analyst reads Pulse Biosciences's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 1 | 0 | 0 | 0 | |
| -11 | 0 | 0 | -0 | |
| -58 | -44 | -56 | -77 | |
| -57 | -42 | -55 | -76 | |
| -59 | -42 | -54 | -73 | |
| -1.69 | -0.85 | -0.92 | -1.08 | |
| -1,606.3% | – | – | -54.0% | |
| -8,293.9% | – | – | -21,982.6% | |
| -8,357.9% | – | – | -20,794.6% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 78 | 59 | 132 | 95 |
| Cash | 61 | 44 | 118 | 81 |
| Total debt | 76 | 9 | 9 | 8 |
| Total liabilities | 80 | 15 | 18 | 14 |
| -2 | 44 | 115 | 81 | |
| 35 | 50 | 58 | 67 | |
| -62.2% | -64.3% | -35.9% | -68.9% | |
| 2,602.5% | -95.2% | -46.7% | -90.2% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -47 | -33 | -36 | -54 | |
| 0 | 0 | 0 | 0 | |
| -47 | -33 | -36 | -54 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 5 | 7 | 14 | 21 |
Valuation
- –
- –
- –
- 47.1×
- 10,599.5×
- –
- –
- -1.5%
- -2.0%
- 0.0%
Profitability
- -54.0%
- -21,982.6%
- -20,794.6%
- -9,824.9%
- -70.7%
- -59.3%
- -86.7%
- -91.4%
- -108.7%
- 6,258.1%
Growth
- −20.6%
- –
- −49.3%
- –
- +25.0%
Financial health
- -1.0×
- 0.09
- 8.8%
- –
- 10.53
- 7.24
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 3%of 952
Bottom 5%of 886
Bottom 31%of 987
What analysts expect
- Average price target
- $30.00
- Range
- $30.00 – $30.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 4, 2026 | -0.27 | -0.32 | +15.6% |
| Feb 19, 2026 | -0.26 | -0.27 | +1.9% |
| Nov 5, 2025 | -0.29 | -0.31 | +6.5% |
| Aug 12, 2025 | -0.28 | -0.26 | −7.7% |
| May 8, 2025 | -0.17 | – | – |
| Mar 27, 2025 | -0.17 | -0.24 | +29.2% |
| Oct 30, 2024 | -0.16 | -0.24 | +33.3% |
| Aug 12, 2024 | -0.20 | -0.24 | +16.7% |
News
Why Pulse Biosciences Stock Popped TodayYahoo Finance · Sep 9, 2026Jensen Huang's AI Capex Pulse CheckYahoo Finance · Sep 9, 2026Credit card delinquencies tick up, net charge-offs decline: July Credit PulseSeeking Alpha · Aug 18, 2026The newest story we have is from Sep 9, 2026.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
39No pass
Philip Fisher
28No pass
Peter Lynch
39No pass
Joel Greenblatt
0No pass
Charlie Munger
27No pass
Terry Smith
23No pass
Questions about Pulse Biosciences
Is Pulse Biosciences a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Pulse Biosciences AI analysis
What does Pulse Biosciences do?
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It is in Medical Instruments & Supplies.
Does Pulse Biosciences pay a dividend?
No. Pulse Biosciences does not pay a dividend at the moment.
Is Pulse Biosciences stock halal?
Yes. Pulse Biosciences passes our halal screen: its business is permitted and its debt is 0.2% of its market value, under the 30% limit. How we check
How has Pulse Biosciences stock done over the past year?
Up 256.7% over the past twelve months, to $50.44. It traded between $12.66 and $58.17 and is 13.3% below its high.
Who are Pulse Biosciences's competitors?
The largest listed companies in the same industry are Intuitive Surgical, EssilorLuxottica Société anonyme, Becton, Dickinson and and Medline. The peers table on this page compares their profit, growth and price with Pulse Biosciences's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.